These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35188142)

  • 1. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
    Paton DM
    Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loteprednol 0.25% (Eysuvis) for dry eye disease.
    Med Lett Drugs Ther; 2021 May; 63(1624):75-77. PubMed ID: 33976092
    [No Abstract]   [Full Text] [Related]  

  • 3. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
    Comstock TL; Sheppard JD
    Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.
    Gupta PK; Venkateswaran N
    Ther Adv Ophthalmol; 2021; 13():25158414211012797. PubMed ID: 34017938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease.
    Venkateswaran N; Bian Y; Gupta PK
    Clin Ophthalmol; 2022; 16():349-355. PubMed ID: 35173413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study.
    Barabino S; Montaldo E; Mingari MC; Mazzotta C; Giuffrida S; Rolando M
    Eur J Ophthalmol; 2022 Jul; 32(4):2452-2458. PubMed ID: 34585595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged Release Niosomes For Ocular Delivery of Loteprednol: Ocular Distribution Assessment on Dry Eye Disease Induced Rabbit Model.
    Ozdemir S; Uner B
    AAPS PharmSciTech; 2024 May; 25(5):119. PubMed ID: 38816667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loteprednol combined with sodium hyaluronate in the treatment of dry eye disease and its effect on TNF-α and CXCL10 in tears.
    Chen W; Shi XL; He XH; Mao YH; Li C; Dong N
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1825-1829. PubMed ID: 33103412
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S; Goa KL
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the treatment of dry eye with Loteprednol Etabonate].
    Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.